Day One Biopharmaceuticals, Inc. (DAWN) Revenue History
Annual and quarterly revenue from 2019 to present
DAWN Revenue Over Time (2019–2025)
DAWN Revenue Growth History
1 of 1 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- +20.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $53.7M | +83.9% |
| Q3 2025 | $39.8M | -57.6% |
| Q2 2025 | $33.9M | +313.9% |
| Q1 2025 | $30.8M | — |
| Q4 2024 | $29.2M | — |
| Q3 2024 | $93.8M | — |
| Q2 2024 | $8.2M | — |
| Q1 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
DAWN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
DAWN Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 22, 2026, Day One Biopharmaceuticals, Inc. (DAWN) generated trailing twelve-month (TTM) revenue of $158.2 million, reflecting explosive growth of +83.9% year-over-year. The most recent quarter (Q4 2025) recorded $53.7 million in revenue, up 35.0% sequentially.
Historical Growth Trajectory
DAWN's historical revenue data shows various trends over time. Day One Biopharmaceuticals, Inc.'s highest annual revenue of $158.2 million was recorded in 2025, an all-time high.
Revenue by Segment
DAWN's revenue is primarily driven by Product (98%), and License (2%). With over half of revenue concentrated in Product, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KURA (+5.4% YoY), TGTX (+81.3% YoY), and RCUS (+67.4% YoY) — DAWN has outperformed the peer group in revenue growth. Compare DAWN vs KURA →
DAWN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DAWNCurrent | $158M | +83.9% | - | -80.8% | |
 KURA | $67M | +5.4% | - | -449.9% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
DAWN Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $158.2M | +20.6% | $141.0M | 89.1% | $-127,750,000 | -80.8% |
| 2024 | $131.2M | - | $125.9M | 96.0% | $-217,270,000 | -165.7% |
| 2023 | $0 | - | $-383,000 | - | $-206,064,000 | - |
| 2022 | $0 | - | $-531,000 | - | $-146,909,000 | - |
| 2021 | $0 | - | $-199,000 | - | $-72,743,000 | - |
| 2020 | $0 | - | $-155,000 | - | $-13,782,000 | - |
| 2019 | $0 | - | $0 | - | $-14,905,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DAWN — Frequently Asked Questions
Quick answers to the most common questions about buying DAWN stock.
Is DAWN's revenue growth accelerating or slowing?
DAWN revenue growth is accelerating. TTM revenue reached $158M, up +83.9% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is DAWN's revenue history from 2019 to 2026?
Day One Biopharmaceuticals, Inc. (DAWN) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $158M, growing at +83.9% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DAWN's long-term revenue growth rate (CAGR)?
Day One Biopharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +83.9% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DAWN.
Why does DAWN's quarterly revenue fluctuate?
DAWN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Day One Biopharmaceuticals, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is DAWN's revenue distributed by segment?
DAWN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DAWN's revenue compare to industry peers?
Day One Biopharmaceuticals, Inc. (DAWN) with TTM revenue of $158M and +83.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.